NSE
SPARC

Sun Pharma Advanced Research Company Limited

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Sun Pharma Advanced Research Company Limited Stock Price

Vitals

Today's Low:
₹237.3
Today's High:
₹255.15
Open Price:
₹251.55
52W Low:
₹160.5
52W High:
₹265.75
Prev. Close:
₹253.5
Volume:
119052

Company Statistics

Market Cap.:
₹74.32 billion
Book Value:
15.801
Revenue TTM:
₹2.34 billion
Operating Margin TTM:
-105.87%
Gross Profit TTM:
₹2.10 billion
Profit Margin:
-100.56%
Return on Assets TTM:
-25.18%
Return on Equity TTM:
-81.83%

Company Profile

Sun Pharma Advanced Research Company Limited had its IPO on under the ticker symbol SPARC.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Sun Pharma Advanced Research Company Limited has a staff strength of 407 employees.

Stock update

Shares of Sun Pharma Advanced Research Company Limited opened at ₹251.55 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹237.3 - ₹255.15, and closed at ₹239.05.

This is a -5.7% slip from the previous day's closing price.

A total volume of 119,052 shares were traded at the close of the day’s session.

In the last one week, shares of Sun Pharma Advanced Research Company Limited have slipped by -4.15%.

Sun Pharma Advanced Research Company Limited's Key Ratios

Sun Pharma Advanced Research Company Limited has a market cap of ₹74.32 billion, indicating a price to book ratio of 33.5601 and a price to sales ratio of 42.7934.

In the last 12-months Sun Pharma Advanced Research Company Limited’s revenue was ₹2.34 billion with a gross profit of ₹2.10 billion and an EBITDA of ₹-2391376128. The EBITDA ratio measures Sun Pharma Advanced Research Company Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sun Pharma Advanced Research Company Limited’s operating margin was -105.87% while its return on assets stood at -25.18% with a return of equity of -81.83%.

In Q2, Sun Pharma Advanced Research Company Limited’s quarterly earnings growth was a positive 0% while revenue growth was a negative 15.8%.

Sun Pharma Advanced Research Company Limited’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at ₹-7.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sun Pharma Advanced Research Company Limited’s profitability.

Sun Pharma Advanced Research Company Limited stock is trading at a EV to sales ratio of 45.2056 and a EV to EBITDA ratio of -30.5907. Its price to sales ratio in the trailing 12-months stood at 42.7934.

Sun Pharma Advanced Research Company Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
₹8.30 billion
Total Liabilities
₹1.79 billion
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
0%

Sun Pharma Advanced Research Company Limited ended 2024 with ₹8.30 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹8.30 billion while shareholder equity stood at ₹5.13 billion.

Sun Pharma Advanced Research Company Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹1.79 billion in other current liabilities, in common stock, ₹-15918134000.00 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹5.80 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

Sun Pharma Advanced Research Company Limited’s total current assets stands at ₹4.55 billion while long-term investments were ₹0 and short-term investments were ₹4.06 billion. Its net receivables were ₹327.10 million compared to accounts payable of ₹1.48 billion and inventory worth ₹0.

In 2024, Sun Pharma Advanced Research Company Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Sun Pharma Advanced Research Company Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price
₹239.05
52-Week High
₹265.75
52-Week Low
₹160.5
Analyst Target Price

Sun Pharma Advanced Research Company Limited stock is currently trading at ₹239.05 per share. It touched a 52-week high of ₹265.75 and a 52-week low of ₹265.75. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹232.21 and 200-day moving average was ₹207.75 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 7445.2% of the company’s stock are held by insiders while 157.6% are held by institutions.

Frequently Asked Questions About Sun Pharma Advanced Research Company Limited

The stock symbol (also called stock or share ticker) of Sun Pharma Advanced Research Company Limited is SPARC

The IPO of Sun Pharma Advanced Research Company Limited took place on

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
₹0.78
0.02
+2.63%
₹98.61
-1.46
-1.46%
₹234
0
0%
₹441.55
-11.4
-2.52%
₹36.93
5.42
+17.2%
₹0.01
-0.06
-92.24%
₹4.27
0.08
+1.91%
₹7.51
0.02
+0.27%
₹37.58
0.48
+1.29%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, dermatology, and Immunology. The company offers Elepsia XR, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension; and Phenobarbital injection for the treatment of neonatal seizures. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson’s disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. The company was incorporated in 2006 and is based in Mumbai, India.

Address